Bipartisan US senators reached a deal to cap insulin prices at $35 per month to aid millions with diabetes. The proposal includes a pilot program for uninsured patients and needs Senate and Trump approval. Consequently, insulin producer stocks like Sanofi, Eli Lilly, and Novo Nordisk gained in pre-market trading.